Clinical Trials Logo

Peroxisomal Disorders clinical trials

View clinical trials related to Peroxisomal Disorders.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01626092 Completed - Clinical trials for Lysosomal Storage Disease

Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders

Start date: July 11, 2012
Phase: N/A
Study type: Interventional

This study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) in patients with high-risk lysosomal and peroxisomal disorders using a novel conditioning regimen for hematopoietic cell transplantation (HCT). After a reduced-intensity conditioning regimen using volumetric-modulated arc therapy (VMAT)-delivered low-dose total body irradiation (TBI) with highly conformal marrow boosting, patients will be transplanted using either a related or unrelated allograft. The cell source may be marrow, peripheral blood or cord blood based on donor availability.

NCT ID: NCT01043640 Completed - Hunter Syndrome Clinical Trials

Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders

Start date: December 2009
Phase: Phase 2
Study type: Interventional

Rationale: Chemotherapy administration before a donor stem cell transplant is necessary to stop the patient's immune system from rejecting the donor's stem cells. When healthy stem cells from a donor are infused into the patient, the donor white blood cells can provide the missing enzyme that causes the metabolic disease. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving a monoclonal antibody, alemtuzumab, before transplant and cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. This may be an effective treatment for inherited metabolic disorders. Purpose: The design of this study is to achieve donor cell engraftment in patients with standard-risk inherited metabolic diseases with limited peri-transplant morbidity and mortality. This will be achieved through the administration of the chemotherapy regimen described. The intention is to follow transplanted patient for years after transplant monitoring them for complications of their disease and assisting families with a multifaceted interdisciplinary approach.

NCT ID: NCT00007020 Completed - Cholestasis Clinical Trials

Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid

Start date: January 1992
Phase: Phase 3
Study type: Interventional

OBJECTIVES: I. To Evaluate the therapeutic efficacy of cholic acid during provision of compassionate treatment to patients with identified inborn errors of bile acid synthesis and metabolism II. To assess the safety and tolerability of cholic acid

NCT ID: NCT00004348 Completed - Clinical trials for Peroxisomal Disorders

Study of Protein Translocation in Patients With Beta-Oxidation Disorders

Start date: September 1995
Phase:
Study type: Observational

OBJECTIVES: I. Characterize inheritance patterns of mutations in patients with beta-oxidation disorders.